PMEF
FOLD

Point72 Middle East FZE’s Amicus Therapeutics FOLD Stock Holding History

Point72 Middle East FZE’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,913
Closed -$132K – 1722
2023
Q1 		$132K Buy
11,913
+5,247
+79% +$64.7K ﹤0.01% 1043
2022
Q4 		$81.4K Buy
+6,666
New +$75K ﹤0.01% 1338

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Point72 Middle East FZE's FOLD Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Amicus Therapeutics (FOLD) in Q2 2023, closing a stake of 11,913 shares — an estimated $132K sold.

Point72 Middle East FZE first reported a position in FOLD in Q4 2022 and held it in 2 quarters. The position peaked at $132K in Q1 2023. 216 funds tracked by Wall St. Rank hold FOLD as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Amicus Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 11,913 Amicus Therapeutics shares in Q2 2023, an estimated $132K.
  • Point72 Middle East FZE first reported a position in Amicus Therapeutics in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's Amicus Therapeutics position peaked at $132K in Q1 2023.
  • 216 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.